Our Story
AlphaRose Therapeutics was founded by Casey McPherson, lead singer and song-writer, entrepreneur and father to Rose. As a baby, Rose was diagnosed with a rare genetic disease.
Now eight years old, she has to face the world without words, scared by her seizures, unable to feed or take care of herself, and often alone.
From a Father's Fight to a Global Solution: The Evolution of AlphaRose Therapeutics
Casey has been fighting for his daughter, and other children affected by genetic diseases, since 2016. He has become a leading voice in the rare disease field through his non-profit foundation To Cure A Rose Foundation, and Contract Research Organization, RareLabs.
In under a year, Casey and his science team successfully developed a preclinical treatment for his daughter's disease.
Throughout this journey, Casey identified a critical need for an innovative business model in the biotech and pharmaceutical sectors to ensure that their process could reach millions of children like Rose — an area that many other companies have overlooked. In 2024, he founded AlphaRose Therapeutics to address this gap.
Legendary Experience Meets Radical Innovation: The Vision Behind AlphaRose Therapeutics
Public-benefit corporation, AlphaRose Therapeutics, brings together Casey McPherson with industry leaders Belinda Termeer, Masako Nakamura, and Alan Walts, who worked alongside Henri Termeer at Genzyme in pioneering the field of rare disease biotech.
Together, they are building a precision medicine company to change how the industry develops and commercializes genetic disease treatments.
Our Mission
To develop and commercialize genetic treatments for suffering patients of small populations.
Our Vision
To eradicate genetic disease by 2040 and usher in a new age of accessible personalized medicines for patients.
Our Legacy
To leverage decades of pioneering biotech expertise to bridge the gap between scientific discovery and global patient delivery.
Meet the Team
Casey McPherson
Co-Founder & CEO
Rose's father. Built To Cure A Rose Foundation, assembled the team that created Rosiphersen in under a year, and drives the company's vision, culture, and fundraising.
Masako Nakamura
COO & President
Oversees clinical development, commercialization, and pipeline operations. Leads execution of Rosiphersen's path to market and manages grant funding strategy.
Robert Cabrera, Ph.D.
Chief Scientific Officer
Baylor College of Medicine. Leads all preclinical work across indications and oversees new technology platform development, including biomarker and toxicity programs.
Jeffrey Brown, Ph.D., MBA
Head of R&D
20+ years in preclinical drug development across Pfizer, BMS, Alexion, Voyager, and Wave Life Sciences. Has advanced multiple programs from concept to clinical candidate across RNA, AAV, and small molecule modalities.
Get in Touch
We're Here to Help
Whether you have a project in mind, need guidance, or want to explore collaboration opportunities — reach out anytime. Our team will respond quickly and provide everything you need to move forward.
Time is life.
Every week that passes without treatment is a week a child's disease progresses. We don't have the luxury of moving at the pace of traditional biotech. Neither do they.